JP4568385B2 - Intermittent claudication - Google Patents
Intermittent claudication Download PDFInfo
- Publication number
- JP4568385B2 JP4568385B2 JP09657796A JP9657796A JP4568385B2 JP 4568385 B2 JP4568385 B2 JP 4568385B2 JP 09657796 A JP09657796 A JP 09657796A JP 9657796 A JP9657796 A JP 9657796A JP 4568385 B2 JP4568385 B2 JP 4568385B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- intermittent claudication
- hydrogen atom
- intermittent
- peripheral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 206010022562 Intermittent claudication Diseases 0.000 title claims description 39
- 208000021156 intermittent vascular claudication Diseases 0.000 title claims description 38
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 14
- 229940079593 drug Drugs 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 14
- 239000004480 active ingredient Substances 0.000 claims description 13
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 13
- 239000001301 oxygen Substances 0.000 claims description 13
- 229910052760 oxygen Inorganic materials 0.000 claims description 13
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 12
- 210000003205 muscle Anatomy 0.000 claims description 11
- 238000004497 NIR spectroscopy Methods 0.000 claims description 10
- 210000003141 lower extremity Anatomy 0.000 claims description 10
- -1 m-methoxyphenyl Chemical group 0.000 claims description 9
- 238000011156 evaluation Methods 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 208000035475 disorder Diseases 0.000 claims description 6
- 125000005843 halogen group Chemical group 0.000 claims description 6
- 150000002148 esters Chemical class 0.000 claims description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
- 230000002093 peripheral effect Effects 0.000 claims description 5
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- INGWEZCOABYORO-UHFFFAOYSA-N 2-(furan-2-yl)-7-methyl-1h-1,8-naphthyridin-4-one Chemical compound N=1C2=NC(C)=CC=C2C(O)=CC=1C1=CC=CO1 INGWEZCOABYORO-UHFFFAOYSA-N 0.000 claims description 4
- 108010064719 Oxyhemoglobins Proteins 0.000 claims description 4
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims description 4
- 108010002255 deoxyhemoglobin Proteins 0.000 claims description 4
- 230000006872 improvement Effects 0.000 claims description 4
- 208000030175 lameness Diseases 0.000 claims description 4
- 230000003836 peripheral circulation Effects 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- 239000012453 solvate Substances 0.000 claims description 3
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 2
- 230000007423 decrease Effects 0.000 claims 2
- 238000013210 evaluation model Methods 0.000 claims 1
- 238000004904 shortening Methods 0.000 claims 1
- 239000000243 solution Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 210000001105 femoral artery Anatomy 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010069729 Collateral circulation Diseases 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 208000021328 arterial occlusion Diseases 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 238000011587 new zealand white rabbit Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 229960001412 pentobarbital Drugs 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000002431 aminoalkoxy group Chemical group 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 239000003420 antiserotonin agent Substances 0.000 description 1
- 210000000544 articulatio talocruralis Anatomy 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009530 blood pressure measurement Methods 0.000 description 1
- PQRJKIYUDHXGLQ-UHFFFAOYSA-N butanedioic acid;hydrochloride Chemical compound Cl.OC(=O)CCC(O)=O PQRJKIYUDHXGLQ-UHFFFAOYSA-N 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 125000006309 butyl amino group Chemical group 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000024980 claudication Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 125000001245 hexylamino group Chemical group [H]N([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 210000003090 iliac artery Anatomy 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 1
- 125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 210000003497 sciatic nerve Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
【０００１】
【発明の属する技術分野】
本発明は、アミノアルコキシビベンジル類を有効成分とする間歇性跛行、特に末梢循環障害に基づく間歇性跛行の改善薬に関するものである。
【０００２】
【従来の技術及び発明が解決しようとする課題】
末梢循環障害の中でも間歇性跛行を訴える患者は多く、年々患者数は増加している。間歇性跛行はおもに四肢主幹動脈の慢性閉塞（閉塞性動脈硬化症、閉塞性血栓血管炎など）に伴う症状で、労作に伴って四肢の筋肉の虚血がもたらされ、筋虚血に起因する鈍痛・しびれなどで運動の持続が困難となるが、安静により再度運動が可能になる状態をいう。その主な原因は、動脈硬化でのコレステロールの内腔への蓄積、血栓の生成であると考えられている（須階二郎ら 現代医療２０，２８０−２８４，１９８８）。
【０００３】
間歇性跛行症状の従来の評価法は、患者の主観的訴えに基づいた跛行距離の長短で行われているが、これは客観性や再現性に乏しい欠点がある。また足関節部圧測定法は、安静時の値で運動時の病態を推測するという点で問題がある。このように間歇性跛行については適切な客観的評価法が確立されていないので、有効な薬剤も開発されていない。臨床的には、保存的手術適応外治療として、抗血小板剤、血管拡張剤などが主に用いられている。
【０００４】
近年、近赤外線分光による運動負荷中の下肢筋肉内酸素動態の測定が、非侵襲かつ簡便な客観的評価法として注目されており（小見山高士ら 医学のあゆみ，１６６，８０７−８，１９９４、市来正隆ら 脈管学３５（１），５３−５９，１９９５、重松宏 ＭＥＤＩＣＡＬ ＤＩＧＥＳＴ，４４（３），１１−１４，１９９５）、この客観的評価法で有効性を示す間歇性跛行の改善薬が切望されている。しかし、間歇性跛行の動物モデルは現在までにまったく報告されておらず、治療薬も開発されていない。
【０００５】
一方、アミノアルコキシビベンジル類は抗血小板作用・抗セロトニン作用を有することが開示されており（特開昭５８−０３２８４７、特開平０２−３０４０２２）、血栓症・微小循環障害に効果が期待できる。しかし、これらが間歇性跛行改善作用を有することは知られていない。
【０００６】
【課題を解決するための手段】
本発明者らは、独自に間歇性跛行の動物モデルを作成し、これを用いて検討した結果、下記一般式（１）で表わされるアミノアルコキシビベンジル類が間歇性跛行に対し有効であることを見出した。
【０００７】
【化３】
（ただし、式中Ｒ1 は水素原子、ハロゲン原子、Ｃ1 〜Ｃ5 のアルコキシ基、またはＣ2 〜Ｃ6 のジアルキルアミノ基を表わし、Ｒ2 は水素原子、ハロゲン原子またはＣ1 〜Ｃ5 のアルコキシ基を表わし、Ｒ3 は水素原子、ヒドロキシル基、−Ｏ−（ＣＨ2 ）n −ＣＯＯＨ（式中、ｎは１〜５の整数を表わす。）、または−Ｏ−ＣＯ−（ＣＨ2 ）l −ＣＯＯＨ（式中、ｌは１〜３の整数を表わす。）を表わし、Ｒ4 は
【０００９】
【化４】
（式中、Ａはカルボキシル基で置換されていてもよいＣ３ 〜Ｃ５ のアルキレン基を表わす）を表わし、ｍは０〜５の整数を表わす。）
その他、本発明の要旨として以下が挙げられる。
（２）（±）−１−［０−［２−（ｍ−メトキシフェニル）エチル］フェノキシ］−３−（ジメチルアミノ）−２−プロピル水素スクシナート塩酸塩を有効成分とすることを特徴とする前記の間歇性跛行改善薬。
（３）末梢循環障害に基づく間歇性跛行に対する改善薬であることを特徴とする前記の間歇性跛行改善薬。
（４）末梢循環障害が末梢動脈硬化症又は末梢動脈閉塞症であることを特徴とする前記の間歇性跛行改善薬。
（５）運動負荷時の筋肉内酸素動態を改善することを特徴とする前記の間歇性跛行改善薬。
（６）下肢筋肉内の酸素動態を改善することを特徴とする前記の間歇性跛行改善薬。
（７）近赤外線分光を用いて測定することを特徴とする前記の間歇性跛行改善薬。
（８）間歇性跛行に対する客観的評価モデルを用いることを特徴とする間歇性跛行改善薬の評価方法。
（９）筋肉内酸素動態を近赤外線分光により定量測定することを特徴とする前記の評価方法。
（１０）前記の評価方法により得られることを特徴とする間歇性跛行改善薬。
（１１）一般式（１）で表わされるアミノアルコキシビベンジル類、薬学上許容し得るその塩、エステル及びそれらの溶媒和物から選ばれる化合物を有効成分とすることを特徴とする前記の間歇性跛行改善薬。
（１２）（±）−１−［０−［２−（ｍ−メトキシフェニル）エチル］フェノキシ］−３−（ジメチルアミノ）−２−プロピル水素スクシナート塩酸塩を有効成分とすることを特徴とする前記の間歇性跛行改善薬。
【００１１】
【発明の実施の形態】
本発明について詳細に説明すると、本発明で使用する一般式（１）で表わされるアミノアルコキシビベンジル類において、Ｒ1 は水素原子；塩素原子、弗素原子等のハロゲン原子；メトキシ基、エトキシ基、ブトキシ基等のＣ1 〜Ｃ5 のアルコキシ基：ジメチルアミノ基、ジエチルアミノ基、メチルエチルアミノ基等のＣ2 〜Ｃ6 のジアルキルアミノ基を表わす。Ｒ2 は水素原子；塩素原子、弗素原子等のハロゲン原子：メトキシ基、エトキシ基、ブトキシ基等のＣ1 〜Ｃ5 のアルコキシ基を表わす。Ｒ3 は水素原子：ヒドロキシル基；−Ｏ−（ＣＨ2 ）2 −ＣＯＯＨ，−Ｏ−（ＣＨ2 ）3 −ＣＯＯＨ等の−Ｏ−（ＣＨ2 ）n −ＣＯＯＨ（ｎは１〜５の整数を表わす）；−Ｏ−ＣＯ−（ＣＨ2 ）2 −ＣＯＯＨ，−Ｏ−ＣＯ−（ＣＨ2 ）3 −ＣＯＯＨ等の−Ｏ−ＣＯ−（ＣＨ2 ）l −ＣＯＯＨ（ｌは１〜３の整数を表わす）を表わす。Ｒ4 はアミノ基、メチルアミノ基、エチルアミノ基、ブチルアミノ基、ヘキシルアミノ基、ヘプチルアミノ基、ジメチルアミノ基、ジエチルアミノ基、メチルエチルアミノ基等を表わすか、又はトリメチレンアミノ基、ペンタメチレンアミノ基、ポリメチレン鎖の中央にカルボキシル基が置換した３−カルボキシペンタメチレンアミノ基等の環にカルボキシル基が置換していてもよい４〜６員のポリメチレンアミノ基を表わす。
本発明で用いる一般式（１）で表わされるアミノアルコキシビベンジル類において、アミノアルコキシ基
【００１２】
【化５】
はフェニル基の２−位に結合しているのが好ましい。また、一般式（１）において、Ｒ1 は水素原子、Ｃ1 〜Ｃ5 のアルコキシ基、又はＣ2 〜Ｃ6 のジアルキルアミノ基が好ましく、Ｒ2 は水素原子が好ましく、Ｒ4 は少くとも１個のＣ1 〜Ｃ8 のアルキル基を有するアミノ基又はトリメチレン基ないしはペンタメチル基を有する４〜６員のポリメチレンアミノ基であるのが好ましく、ｍは０〜２の整数であるのが好ましい。
【００１４】
本発明では、一般式（１）で表わされる化合物の薬学的に許容される塩やエステルも用いることができる。このような塩やエステルを形成する酸としては、例えば塩化水素酸、臭化水素酸、硫酸、リン酸、硝酸、酢酸、コハク酸、アジピン酸、プロピオン酸、酒石酸、マレイン酸、蓚酸、クエン酸、安息香酸、トルエンスルホン酸、メタンスルホン酸等が用いられる。また、一般式（１）で表わされる化合物、その塩やエステルの溶媒和物、例えば水和物も用いることができる。
これらのうちで特に好ましいのは、下記（２）式で表わされる（±）−１−〔０−〔２−（ｍ−メトキシフェニル）エチル〕フェノキシ〕−３−（ジメチルアミノ）−２−プロピル水素スクシナートの塩酸塩である。
【００１５】
【化６】
本発明で用いる一般式（１）で表わされるアミノアルコキシビベンジル類は公知化合物であり、例えば特開昭５８−３２８４７号公報に記載の方法により容易に合成することができる。
本発明に係る間歇性跛行改善薬の投与方法は任意である。
即ち、皮下注射、静脈内注射、筋肉注射、腹腔内注射等の非経口投与も、また経口投与も可能である。
【００１７】
投与量は患者の年齢、健康状態、体重、同時処理があるならばその種類、処置頻度、所望の効果の性質等により決定される。
一般的に有効成分の１日投与量は０．５〜５０ｍｇ／ｋｇ体重、通常１〜３０ｍｇ／ｋｇ体重であり、１回あるいはそれ以上投与される。
本発明化合物を経口投与する場合は、錠剤、カプセル剤、粉剤、液剤、エリキシル剤等の形態で、また、非経口投与の場合は、液剤あるいは懸濁化剤等の殺菌した液状の形態で用いられる。上述の様な形態で用いられる場合、固体あるいは液体の毒性のない製剤的担体が組成に含まれ得る。
【００１８】
固体担体の例としては通常のゼラチンタイプのカプセルが用いられる。また、有効成分を補助薬とともに、あるいはそれなしに錠剤化、粉末包装される。
これらのカプセル、錠剤、粉末は一般的に５〜９５％、好ましくは２５〜９０％重量の有効成分を含む。
即ち、これらの投与形式では１回の投与につき５〜５００ｍｇ、好ましくは２５〜２５０ｍｇの有効成分を含有するのがよい。
【００１９】
液状担体としては水あるいは石油、ピーナツ油、大豆油、ミネラル油、ゴマ油等の動植物起源の、または合成の油が用いられる。
また、一般に生理食塩水、デキストロールあるいは類似のショ糖溶液、エチレングリコール、プロピレングリコール、ポリエチレングリコール等のグリコール類が液状担体として好ましく、特に生理食塩水を用いた注射液の場合には通常０．５〜２０％、好ましくは１〜１０％重量の有効成分を含むようにする。
【００２０】
【実施例】
以下に実施例により、本発明をさらに具体的に説明するが、本発明はこの実施例に限定されるものではない。
間歇性跛行モデルの作成
雄性Ｎｅｗ Ｚｅａｌａｎｄ Ｗｈｉｔｅ Ｒａｂｂｉｔ １４羽を第１群（９羽）と第２群（５羽）とに無作意に分けた。
両群ともペントバルビタール麻酔下にて、鼠蹊部で右大腿動脈を露出し、カテーテルを７ｃｍ挿入し、右腸骨動脈内で直径３ｍｍに膨張させたまま引き抜くバルーン障害を３回施行した後、大腿動脈を結索した。カテーテルとしてはバクスター社のＦｏｇａｒｔｙ（サイズ：２フレンチ）を用いた。手術１週間後に第１群、２週間後に第２群を、それぞれペントバルビタール麻酔下、仰臥位にて下肢後面を切開した。右ひ腹筋内側部に直接近赤外線分光のプローブを装着し、運動負荷として右坐骨神経に１Ｈｚ、２分間の電気刺激を加えた。負荷後安静状態において運動中低下していたオキシヘモグロビンが回復してデオキシヘモグロビンと交差するまでの時間（回復時間）を測定した。近赤外線分光の測定にはＯＭ−１００（島津製作所）を用い、近赤外光の送受光間距離は５ｍｍとした。結果を表１に示す。
【００２１】
また、大腿動脈を結索しない場合、結索直後及び結索１週間後の下肢筋肉内の酸素動態パターンを模式的に図１〜図３に示す。
本モデルは、臨床での間歇性跛行患者と同じパターン（小見山高士ら 医学のあゆみ，１６６，８０７−８，１９９４、市来正隆ら 脈管学３５（１），５３−５９，１９９５）を示しており、本モデルにより運動筋酸素動態を客観的に定量測定することができる。即ち、本モデルは、間歇性跛行に対する客観的動物モデルである。
【００２２】
【表１】
間歇性跛行の重症度の指標である回復時間が経時的に短縮したのは、時間がたつに従って、側副血行路が発達し、筋肉内の酸素動態が改善されたものと考えられる。
【００２４】
実施例
雄性Ｎｅｗ Ｚｅａｌａｎｄ Ｗｈｉｔｅ Ｒａｂｂｉｔ １６羽を、薬剤投与群（７羽）と対照群（９羽）とに無作意に分け、モデルと同じ処置を行った。
薬剤投与群には、手術当日から近赤外線分光測定日まで、特開昭５８−３２８４７号公報に記載の方法により得られた（±）−１−〔０−〔２−（ｍ−メトキシフェニル）エチル〕フェノキシ〕−３−ジメチルアミノ−２−プロピル水素スクシナート塩酸塩を１００ｍｇ／ｋｇとなるように、１％トラガント溶液に懸濁して、１日１回経口投与した。対照群にはトラガント溶液を１日１回経口投与した。手術１週間後に近赤外線分光で回復時間を測定した。結果を表２に示す。
【００２５】
【表２】
表２に示したとおり、手術１週間後の回復時間は、対照群に対し、投薬群において有意に短縮し、下肢筋肉酸素動態の改善が見られた。いずれの動物も下肢の虚血壊死はみられなかった。この実験結果から、本発明に係るアミノアルコキシビベンジル類を有効成分とする薬剤は、側副血行路の発達促進あるいは側副血行路の血流維持によって下肢筋肉内の酸素動態を改善し、間歇性跛行改善作用を有することが明らかである。
【００２７】
【発明の効果】
本発明に係るアミノアルコキシビベンジル類を有効成分とする薬剤は、間歇性跛行、およびその病因と考えられる末梢動脈硬化症、末梢動脈閉塞症などの末梢循環障害において、間歇性跛行の改善および予防効果を有することが期待される。
【図面の簡単な説明】
【図１】間歇性跛行モデルにおける下肢筋肉内の酸素動態パターンを近赤外線分光法により測定した場合の模式図。大腿動脈を結索しない場合の図で、正常パターンを示す。
【図２】間歇性跛行モデルにおける下肢筋肉内の酸素動態パターンを近赤外線分光法により測定した場合の模式図。大腿動脈を結索した直後の図で、重症パターンを示す。
【図３】間歇性跛行モデルにおける下肢筋肉内の酸素動態パターンを近赤外線分光法により測定した場合の模式図。大腿動脈を結索後１週間経過した時点の図で、図２よりも軽症パターンを示す。
【符号の説明】
Ｏｘｙ Ｈｂ ： オキシヘモグロビン
Ｄｅｏ Ｈｂ ： デオキシヘモグロビン[0001]
BACKGROUND OF THE INVENTION
The present invention relates to a drug for improving intermittent claudication, particularly intermittent claudication based on peripheral circulatory disturbance, comprising aminoalkoxybibenzyls as an active ingredient.
[0002]
[Prior art and problems to be solved by the invention]
Many patients complain of intermittent claudication among peripheral circulatory disorders, and the number of patients is increasing year by year. Intermittent claudication is a symptom mainly associated with chronic occlusion of the main limb arteries (occlusive arteriosclerosis, obstructive thromboangiitis, etc.). It means that it is difficult to continue exercise due to dull pain, numbness, etc., but it becomes possible to exercise again by resting. It is thought that the main cause is accumulation of cholesterol in the lumen due to arteriosclerosis and generation of a thrombus (Jiro Sukiya et al., Contemporary Medicine 20, 280-284, 1988).
[0003]
Conventional evaluation methods for intermittent claudication are performed with the length of the lameness based on the patient's subjective complaints, but this has a drawback of poor objectivity and reproducibility. In addition, the ankle joint pressure measurement method has a problem in that a pathological condition during exercise is estimated from a value at rest. Thus, since an appropriate objective evaluation method has not been established for intermittent claudication, an effective drug has not been developed. Clinically, antiplatelet agents, vasodilators and the like are mainly used as conservative off-label treatments.
[0004]
In recent years, the measurement of oxygen dynamics in the lower limb muscles during exercise load by near infrared spectroscopy has attracted attention as a non-invasive and simple objective evaluation method (Takashi Komiyama et al., Ayumi, 166, 807-8, 1994, City Masataka Kurusu, Angiology 35 (1), 53-59, 1995, Hiroshi Shigematsu MEDICAL DIGEEST, 44 (3), 11-14, 1995), an agent for improving intermittent claudication that is effective in this objective evaluation method Is anxious. However, no animal model of intermittent claudication has been reported to date and no therapeutic drug has been developed.
[0005]
On the other hand, aminoalkoxybibenzyls have been disclosed to have antiplatelet action and antiserotonin action (Japanese Patent Laid-Open No. 58-032847, Japanese Patent Laid-Open No. 02-304002), and can be expected to be effective for thrombosis and microcirculatory disturbance. However, it is not known that these have an effect of improving intermittent claudication.
[0006]
[Means for Solving the Problems]
The inventors of the present invention independently created an animal model of intermittent claudication, and as a result of studying it, the aminoalkoxybibenzyls represented by the following general formula (1) are effective against intermittent claudication. I found.
[0007]
[Chemical 3]
(Wherein, R 1 represents a hydrogen atom, a halogen atom, a C 1 -C 5 alkoxy group, or a C 2 -C 6 dialkylamino group, and R 2 represents a hydrogen atom, a halogen atom, or C 1 -C 5. R 3 represents a hydrogen atom, a hydroxyl group, —O— (CH 2 ) n —COOH (wherein n represents an integer of 1 to 5), or —O—CO— (CH 2 ) L -COOH (wherein l represents an integer of 1 to 3), and R 4 represents
[Formula 4]
(Wherein, A represents a C3 to C5 alkylene group which may be substituted with a carboxyl group), and m represents an integer of 0 to 5. )
In addition, the gist of the present invention is as follows.
(2) (±) -1- [0- [2- (m-methoxyphenyl) ethyl] phenoxy] -3- (dimethylamino) -2-propyl hydrogen succinate hydrochloride as an active ingredient The above-mentioned intermittent claudication drug.
(3) The above-mentioned intermittent claudication improving drug, which is an improvement drug for intermittent claudication based on peripheral circulation disorder.
(4) The above-mentioned intermittent claudication improving agent, wherein the peripheral circulation disorder is peripheral arteriosclerosis or peripheral arterial occlusion.
(5) The above-mentioned intermittent claudication improver characterized by improving intramuscular oxygen dynamics during exercise load.
(6) The intermittent claudication improver characterized by improving oxygen dynamics in lower limb muscles.
(7) The said intermittent claudication improving agent characterized by measuring using near-infrared spectroscopy.
(8) A method for evaluating an intermittent claudication drug, characterized by using an objective assessment model for intermittent claudication.
(9) The evaluation method described above, wherein the intramuscular oxygen dynamics are quantitatively measured by near infrared spectroscopy.
(10) An intermittent claudication improver obtained by the evaluation method described above.
(11) The above-mentioned intermittentness characterized by comprising as an active ingredient a compound selected from aminoalkoxybibenzyls represented by the general formula (1), pharmaceutically acceptable salts, esters and solvates thereof. Lameness improving drug.
(12) (±) -1- [0- [2- (m-methoxyphenyl) ethyl] phenoxy] -3- (dimethylamino) -2-propyl hydrogen succinate hydrochloride is an active ingredient. The above-mentioned intermittent claudication drug.
[0011]
DETAILED DESCRIPTION OF THE INVENTION
The present invention will be described in detail. In the aminoalkoxybibenzyls represented by the general formula (1) used in the present invention, R 1 is a hydrogen atom; a halogen atom such as a chlorine atom or a fluorine atom; a methoxy group, an ethoxy group, alkoxy C 1 -C 5 or a butoxy group: dimethylamino group, diethylamino group, represents a dialkylamino group of C 2 -C 6 such as a methyl ethylamino group. R 2 represents a hydrogen atom; a halogen atom such as a chlorine atom or a fluorine atom: a C 1 -C 5 alkoxy group such as a methoxy group, an ethoxy group, or a butoxy group. R 3 is a hydrogen atom: a hydroxyl group; -O- (CH 2) 2 -COOH , -O- (CH 2) 3 -O- (CH 2) a -COOH such as n -COOH (n is an integer of from 1 to 5 the expressed); - O-CO- (CH 2) 2 -COOH, -O-CO- ( in CH 2) 3 -COOH, etc. -O-CO- (CH 2) l -COOH (l is 1 to 3 Represents an integer). R 4 represents an amino group, a methylamino group, an ethylamino group, a butylamino group, a hexylamino group, a heptylamino group, a dimethylamino group, a diethylamino group, a methylethylamino group or the like, or a trimethyleneamino group, pentamethylene It represents a 4- to 6-membered polymethyleneamino group in which a carboxyl group may be substituted on a ring such as an amino group and a 3-carboxypentamethyleneamino group substituted with a carboxyl group at the center of the polymethylene chain.
In the aminoalkoxybibenzyls represented by the general formula (1) used in the present invention, an aminoalkoxy group
[Chemical formula 5]
Is preferably bonded to the 2-position of the phenyl group. In general formula (1), R 1 is preferably a hydrogen atom, a C 1 -C 5 alkoxy group, or a C 2 -C 6 dialkylamino group, R 2 is preferably a hydrogen atom, and R 4 is at least It is preferably an amino group having one C 1 -C 8 alkyl group or a trimethylene group or a 4-6 membered polymethyleneamino group having a pentamethyl group, and m is preferably an integer of 0-2. .
[0014]
In the present invention, pharmaceutically acceptable salts and esters of the compound represented by the general formula (1) can also be used. Examples of acids that form such salts and esters include hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, acetic acid, succinic acid, adipic acid, propionic acid, tartaric acid, maleic acid, succinic acid, and citric acid. Benzoic acid, toluenesulfonic acid, methanesulfonic acid and the like are used. Moreover, the solvate of the compound represented by General formula (1), its salt, and ester, for example, a hydrate, can also be used.
Among these, (±) -1- [0- [2- (m-methoxyphenyl) ethyl] phenoxy] -3- (dimethylamino) -2-propyl represented by the following formula (2) is particularly preferable. Hydrogen succinate hydrochloride.
[0015]
[Chemical 6]
The aminoalkoxybibenzyls represented by the general formula (1) used in the present invention are known compounds and can be easily synthesized, for example, by the method described in JP-A-58-32847.
The method for administering the intermittent claudication drug according to the present invention is arbitrary.
That is, parenteral administration such as subcutaneous injection, intravenous injection, intramuscular injection, intraperitoneal injection, or the like is also possible.
[0017]
The dosage is determined by the patient's age, health status, weight, type of treatment, if any, the nature of the desired effect, etc.
In general, the daily dose of the active ingredient is 0.5 to 50 mg / kg body weight, usually 1 to 30 mg / kg body weight, and is administered once or more.
When the compound of the present invention is administered orally, it is used in the form of tablets, capsules, powders, solutions, elixirs, etc. In the case of parenteral administration, it is used in a sterilized liquid form such as solutions or suspending agents. It is done. When used in such a form as described above, a solid or liquid non-toxic pharmaceutical carrier may be included in the composition.
[0018]
As an example of the solid carrier, a normal gelatin type capsule is used. In addition, the active ingredients are tableted and powdered with or without adjuvants.
These capsules, tablets and powders generally contain 5 to 95%, preferably 25 to 90% by weight of active ingredient.
That is, these dosage forms should contain 5 to 500 mg, preferably 25 to 250 mg of active ingredient per administration.
[0019]
As the liquid carrier, water or oil of animal or plant origin such as petroleum, peanut oil, soybean oil, mineral oil, sesame oil, or synthetic oil is used.
In general, physiological saline, dextrol or similar sucrose solution, glycols such as ethylene glycol, propylene glycol, polyethylene glycol and the like are preferable as the liquid carrier, and in the case of an injection solution using physiological saline, it is usually 0.00. It contains 5 to 20%, preferably 1 to 10% by weight of the active ingredient.
[0020]
【Example】
The present invention will be described more specifically with reference to the following examples, but the present invention is not limited to these examples.
Creation of intermittent claudication model 14 male New Zealand White Rabbits were randomly divided into a first group (9) and a second group (5).
In both groups, under pentobarbital anesthesia, the right femoral artery was exposed at the buttocks, the catheter was inserted 7 cm, and the balloon was withdrawn while being inflated to a diameter of 3 mm within the right iliac artery. The artery was connected. Baxter Fogarty (size: 2 French) was used as the catheter. One week after the surgery, the first group and the second group after 2 weeks were incised in the supine position under pentobarbital anesthesia, respectively. A near-infrared spectroscopic probe was directly attached to the inside of the right gastrocnemius muscle, and 1 Hz, 2 minutes of electrical stimulation was applied to the right sciatic nerve as an exercise load. The time (recovery time) until oxyhemoglobin, which had decreased during exercise in a resting state after loading, recovered and crossed with deoxyhemoglobin was measured. For measurement of near infrared spectroscopy, OM-100 (Shimadzu Corporation) was used, and the distance between near infrared light transmission and reception was 5 mm. The results are shown in Table 1.
[0021]
Moreover, in the case where the femoral artery is not tied, FIGS. 1 to 3 schematically show oxygen dynamic patterns in the lower limb muscles immediately after ligation and one week after ligation.
This model shows the same pattern as that of patients with intermittent claudication in clinical practice (Takashi Omiyama et al., Ayumi of Medicine, 166, 807-8, 1994, Masataka Ichiki et al., Angiology 35 (1), 53-59, 1995). This model enables objective and quantitative measurement of exercise muscle oxygen dynamics. That is, this model is an objective animal model for intermittent claudication.
[0022]
[Table 1]
The recovery time, which is an index of the severity of intermittent claudication, has been reduced over time. It is thought that as time passed, the collateral circulation developed and the intramuscular oxygen dynamics improved.
[0024]
EXAMPLE 16 Male New Zealand White Rabbits were randomly divided into a drug administration group (7 birds) and a control group (9 birds), and the same treatment as the model was performed.
In the drug administration group, (±) -1- [0- [2- (m-methoxyphenyl)] obtained by the method described in JP-A-58-32847 from the day of surgery to the day of near infrared spectroscopy measurement. [Ethyl] phenoxy] -3-dimethylamino-2-propyl hydrogen succinate hydrochloride was suspended in a 1% tragacanth solution so as to be 100 mg / kg and orally administered once a day. To the control group, tragacanth solution was orally administered once a day. The recovery time was measured by near infrared spectroscopy one week after the operation. The results are shown in Table 2.
[0025]
[Table 2]
As shown in Table 2, the recovery time one week after the operation was significantly shortened in the dosing group compared with the control group, and improvement in lower limb muscle oxygen dynamics was observed. None of the animals had ischemic necrosis of the lower limbs. From these experimental results, the drug comprising the aminoalkoxybibenzyls according to the present invention as an active ingredient improves oxygen dynamics in the lower limb muscles by promoting the development of the collateral circulation or maintaining the blood flow in the collateral circulation. It is clear that it has the effect of improving sexual claudication.
[0027]
【The invention's effect】
The drug containing aminoalkoxybibenzyls according to the present invention as an active ingredient improves and prevents intermittent claudication in intermittent claudication and peripheral circulation disorders such as peripheral arteriosclerosis and peripheral arterial occlusion considered to be the etiology thereof. Expected to have an effect.
[Brief description of the drawings]
FIG. 1 is a schematic diagram in a case where an oxygen dynamic pattern in a lower limb muscle in an intermittent claudication model is measured by near infrared spectroscopy. A normal pattern is shown in the figure when the femoral artery is not tied.
FIG. 2 is a schematic diagram in a case where an oxygen dynamic pattern in a lower limb muscle in an intermittent claudication model is measured by near infrared spectroscopy. A severe pattern is shown in the figure immediately after the femoral artery is tied.
FIG. 3 is a schematic diagram when the oxygen dynamic pattern in the lower limb muscle in the intermittent claudication model is measured by near infrared spectroscopy. It is a figure at the time when 1 week has passed after the femoral artery is tied, and shows a milder pattern than FIG.
[Explanation of symbols]
Oxy Hb: Oxyhemoglobin Deo Hb: Deoxyhemoglobin
Claims (5)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP09657796A JP4568385B2 (en) | 1996-04-18 | 1996-04-18 | Intermittent claudication |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP09657796A JP4568385B2 (en) | 1996-04-18 | 1996-04-18 | Intermittent claudication |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007285289A Division JP2008074864A (en) | 2007-11-01 | 2007-11-01 | Intermittent claudication |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH09286722A JPH09286722A (en) | 1997-11-04 |
| JP4568385B2 true JP4568385B2 (en) | 2010-10-27 |
Family
ID=14168837
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP09657796A Expired - Fee Related JP4568385B2 (en) | 1996-04-18 | 1996-04-18 | Intermittent claudication |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP4568385B2 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6998121B2 (en) * | 2003-01-23 | 2006-02-14 | Milkhaus Laboratory, Inc. | Method of treatment of connective tissue disorders by administration of streptolysin O |
| WO2003026636A1 (en) * | 2001-09-26 | 2003-04-03 | Mitsubishi Pharma Corporation | Thrombus/thrombogenesis inhibitors |
| KR20060128994A (en) * | 2004-02-02 | 2006-12-14 | 미쯔비시 웰 파마 가부시키가이샤 | Prevention and / or Treatment of Chronic Cerebral Dysfunction |
-
1996
- 1996-04-18 JP JP09657796A patent/JP4568385B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JPH09286722A (en) | 1997-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jacqz-Aigrain et al. | Placebo-controlled trial of midazolam sedation in mechanically ventilated newborn babies | |
| JP5631053B2 (en) | Prevention and / or treatment of portal hypertension | |
| CZ280446B6 (en) | Preparation for administration to men suffering from impotence | |
| JP2003521462A (en) | Use of apomorphine in the manufacture of a medicament for the treatment of organic erectile dysfunction in men | |
| WO1996012480A1 (en) | Polyamine compounds for treating vascular proliferative disorders | |
| JP2008525504A (en) | Method of using resiniferatoxin (RTX) for producing a medicament for treating joint pain and method of applying said medicament | |
| Skouen et al. | Paraplegia following epidural anesthesia: A case report and a literature review | |
| JPH09323927A (en) | Drugs containing carnitine derivatives for the treatment of chronic arteriosclerosis obliterans | |
| JP4568385B2 (en) | Intermittent claudication | |
| Olmstead et al. | Five‐hydroxytryptamine antagonists and feline aortic embolism | |
| JP2002265356A (en) | Agent for treating and / or preventing pain in lumbar disc herniation | |
| Abeshouse et al. | Paraplegia, a rare complication of translumbar aortography | |
| Williams et al. | Alpha-tocopherol in the treatment of intermittent claudication: a preliminary report | |
| JP2008074864A (en) | Intermittent claudication | |
| Guilleminault | Diagnosis, pathogenesis, and treatment of the sleep apnea syndromes | |
| JP2004514740A (en) | Therapeutic treatment | |
| Baker | Anaesthesia and endovascular surgery | |
| Kim et al. | Does desflurane need more irrigating-pump pressure for the visibility in arthroscopic shoulder surgery than sevoflurane? | |
| KR20010102388A (en) | Intermittent claudication remedies | |
| JP2532918B2 (en) | Anti-atherogenic agent containing guanidinobenzoic acid derivative as an active ingredient | |
| Rubinstein | Postprandial drowsiness | |
| Chandra et al. | Comparative Evaluation of Clonidine and Fentanyl as Adjuvants with Levobupivacaine for Postoperative Epidural Analgesia after Total Knee Replacement Surgery-A Randomised Double Blind Study | |
| Krishnendu et al. | Comparative Evaluation of the Effect of Clonidine and Dexmedetomidine as Adjuncts to Lignocaine in Intravenous Regional Anaesthesia in Forearm and Hand Surgeries | |
| Synan | Postoperative management and complications | |
| Devireddy | A Study to Evaluate the Effects of Unilateral Spinal Anaesthesia with Intrathecal Hyperbaric Bupivacaine and Adjuvant Fentanyl Using 27 G Spinal Needle in Elective Lower Limb Surgeries |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070309 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20070427 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070507 Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20070507 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070713 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20070713 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20070713 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20070905 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071004 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071004 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071210 |
|
| A911 | Transfer of reconsideration by examiner before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20071213 |
|
| A912 | Removal of reconsideration by examiner before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20080111 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20071212 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20080528 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20080528 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20090325 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20090325 |
|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20100308 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20100311 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20100809 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130813 Year of fee payment: 3 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |